Mechanism of action
The site of action of the drug is the terminal part of the distal tubules and collecting ducts.
The targets are epithelial sodium channels (ENaC) located on the apical membrane of the cells. Triamterenum is a direct blocker: it physically closes the entry for sodium ions through the channel.
To understand the pharmacology of this group, it is important to distinguish this mechanism from the action of aldosterone antagonists (e.g., Spironolactonum). Antagonists work intracellularly by blocking mineralocorticoid receptors and disrupting the synthesis of new ENaC channels, whereas triamterene acts directly on pre-existing channels.
Pharmacological effects
A key feature of the drug is its unique ability to enhance the excretion of $Na^+$ ions while retaining $K^+$ and $Mg^{2+}$ ions in the body.
- Potency: The intrinsic diuretic effect of the drug is weak (moderate). In terms of efficacy, it is significantly inferior to thiazide and loop diuretics. Within its narrow group, it is also somewhat weaker than Amiloridum (which is excluded from the drug registry in the Russian Federation).
- Duration: The effect lasts for 6–8 hours.
- Effect on homeostasis: The drug does not disturb the acid-base balance, and its activity does not depend on the ambient pH.
Indications for use
- Correction of electrolyte disturbances. Potent diuretics (loop, thiazide, and thiazide-like) share a common side effect — they cause hypokalemia and hypomagnesemia. The rationale for prescribing triamterene is based on eliminating these losses. It is used strictly as part of combination therapy (the classic example: hydrochlorothiazide + triamterene).
- Liddle syndrome. This is a rare hereditary form of arterial hypertension. The pathogenesis of the disease lies in a mutation of ENaC channels, leading to their hyperactivity. Direct sodium channel blockers are the drugs of choice for the pathogenetic treatment of this condition.
Side effects and toxicity
Specific drug toxicity of triamterene is related to the fact that it is a folic acid antagonist (this risk group also includes the antineoplastic drug Methotrexatum and the antiprotozoal drug Pyrimethaminum).
The drug can impair folate metabolism and DNA synthesis. Consequently, its administration can provoke the development of iatrogenic megaloblastic anemia (of the macrocytic hyperchromic type).
Management of complications: If a deficiency develops, folic acid is prescribed orally at 0.005 g/day for a course of 20–30 days. It is important to remember the rule of hematology: if the patient also has pernicious anemia, isolated administration of folic acid without vitamin B12 is unacceptable, as it will not relieve neurological disorders.
Administration guidelines and prescription
Due to its relatively short half-life (6–8 hours), the drug is prescribed in multiple doses — from 2 to 4 times a day. Administration should be carried out strictly in the first half of the day to avoid nocturnal diuresis that disrupts the patient's sleep.
Basic methodological guidelines indicate that administration on an empty stomach is preferable, but specific capsule formulations are often prescribed after meals to minimize gastrointestinal effects.
Prescription writing example:
Rp.: Caps. Triamtereni 0.05 D.t.d. N. 50 S. Take 1-2 capsules orally 2 times a day after meals (in the first half of the day).
Briefly: answers to topical questions
What side effects does triamterene cause?
Triamterene can cause iatrogenic megaloblastic anemia as a side effect. This drug belongs to the folic acid antagonist group and disrupts folate metabolism or DNA synthesis, leading to the development of megaloblastic anemia. This type of anemia is characterized by a macrocytic hyperchromic picture.
What drugs interact with triamterene?
Triamterene is used in combination therapy with potassium-wasting diuretics.
- Thiazide and thiazide-like diuretics (e.g., hydrochlorothiazide) — triamterene is co-prescribed to prevent hypokalemia and hypomagnesemia.
- Loop diuretics — the combination is used to mitigate the side effects of primary diuretics and correct electrolyte disturbances.
TRIamterene — THREE facts: blocks ENaC, saves Potassium, causes Anemia (megaloblastic).
Class and exam questions
Why is triamterene almost never prescribed as monotherapy for edema?
It has a very weak intrinsic diuretic effect. Its main therapeutic value is the ability to spare potassium and magnesium, which is why it is combined with potent diuretics that excrete these electrolytes.
What is the fundamental difference in the mechanism of action between triamterene and spironolactone?
Both drugs spare potassium, but triamterene is a direct blocker that physically closes sodium channels (ENaC) on the membrane. Spironolactone is an aldosterone antagonist; it works inside the cell, suppressing the synthesis of new ENaC channels.
What specific hematological complication can triamterene cause?
Iatrogenic megaloblastic (macrocytic hyperchromic) anemia. The drug is a folic acid antagonist and disrupts DNA synthesis.
What else to study on this topic
- Loop and thiazide diuretics: mechanisms of hypokalemia development
- Liddle syndrome: genetics, pathogenesis, and clinical presentation
- Aldosterone antagonists (spironolactone, eplerenone)
- Megaloblastic anemia: differential diagnosis and principles of treatment
- Physiology of ion reabsorption in the renal collecting ducts
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Triamterene" and 5,304 other pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.